CN Patent

CN102458410A — 治疗实体瘤的方法

Assigned to Gilead Calistoga LLC · Expires 2012-05-16 · 14y expired

What this patent protects

本发明提供涉及用于治疗血液恶性肿瘤和炎性疾病的新治疗策略的方法。特别地，所述方法包含给予式I化合物，或其药学上可接受的盐，或者包含与至少一种药学上可接受的赋形剂混合的此类化合物的药用组合物。

USPTO Abstract

本发明提供涉及用于治疗血液恶性肿瘤和炎性疾病的新治疗策略的方法。特别地，所述方法包含给予式I化合物，或其药学上可接受的盐，或者包含与至少一种药学上可接受的赋形剂混合的此类化合物的药用组合物。

Drugs covered by this patent

umbralisib-tosylate (UMBRALISIB TOSYLATE)

Patent Metadata

Patent number: CN102458410A
Jurisdiction: CN
Classification: —
Expires: 2012-05-16
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Calistoga LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.